NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Medpace Holdings, Inc. (MEDP) Stock Analysis

Medpace Holdings, Inc. (MEDP) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

MEDP

$591.29

−$2.10 (−0.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MEDP with… →

MEDP Key Statistics

As of Sep 4, 2026
Trading
Open
$585.10
Previous Close
$593.39
Day's Range
585.00–596.00
52-Week Range
373.00–677.90
Volume
146.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.15
Valuation
Market Cap
$16.50B
P/E Ratio
34.72
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
30.62
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.77
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.93
EPS (ttm)Profit attributable to each share over the last twelve months.
17.03
Financials (FY)
Revenue (FY)
$2.53B+19.97%
Net Income (FY)
$451.12M+11.56%
Profit marginThe share of revenue left as profit after all costs and taxes.
17.66%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.91M
1-Year Return
+22.59%
Dividend and dates
Earnings Date
October 19, 2026estimated
Avg Volume
301.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MEDP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+5.28%
2025+69.05%
2024+8.38%
2023+44.31%
2022−2.40%
2021+56.35%
2020+65.60%
2019+58.81%
2018+45.97%
2017+0.53%
2016 (partial year)+29.79%

As of September 4, 2026.

MEDP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.53B$451.12M17.8%
2024$2.11B$404.39M19.2%
2023$1.89B$282.81M15.0%
2022$1.46B$245.37M16.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.53B$760.62M$534.94M$451.12M17.8%
2024$2.11B$656.31M$446.87M$404.39M19.2%
2023$1.89B$524.51M$336.83M$282.81M15.0%
2022$1.46B$432.44M$278.70M$245.37M16.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MEDP Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricMEDPDiagnostics & Research medianvs median
P/E34.7233.085% above
P/S ratio5.934.9919% above
Profit margin17.66%0.00%17.7 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Medpace Holdings, Inc. (MEDP) carries a market capitalisation of $16.50B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 6,500 employees.

The 52-week range on file runs from $373.00 to $677.90. MEDP last closed at $591.29 on September 4, 2026. That is −$2.10 (−0.35%) against the previous close. The latest close sits 58.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.53B. That is +19.97% against the prior fiscal year, when revenue was $2.11B. The same year closed with net income of $451.12M. That is +11.56% against the prior fiscal year. Profit margin runs at 17.67%. That is 17.7 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 17.03.

Across the 4 fiscal years on file, revenue moves from $1.46B in 2022 to $2.53B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 34.72 times earnings. That is 4.96% above the Diagnostics & Research median of 33.08. On forward earnings the ratio is 30.62. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.77. The price-to-sales ratio is 5.93. On price-to-sales that is 18.87% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +22.59%. Measured over 10 years, that is +34.42% a year compounded. The reported beta is 1.15. Daily returns over the trailing 10 years annualize to a volatility of 49.67%.

Growth & Income

The record shows no dividend for MEDP.

So far in 2026 the price is +5.28%. The strongest complete calendar year on file is 2025 at +69.05%; the weakest is 2022 at −2.40%. Of the 9 complete calendar years on file, 8 finished higher.

Peer Comparison

Medpace Holdings, Inc. (MEDP) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Medpace Holdings, Inc. MEDP $16.50B 34.7
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Medpace Holdings, Inc. trades at a P/E of 34.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Visit website →